Due to decades of research restrictions in the US and growers’ focus on THC, there are very few human studies that look at CBD and its effects. The strongest evidence we have is that CBD can reduce the frequency of seizures in certain rare pediatric disorders — so much that a CBD-based drug called Epidiolex was FDA-approved in 2018 for this purpose. There is also preliminary human data from small clinical trials with dozens of subjects that suggests CBD may have the potential to be used for conditions like anxiety, schizophrenia, opioid addiction, and Parkinson’s disease. But please note that the participants in these studies generally received several hundreds of milligrams of CBD a day, meaning the 5mg to 25mg of CBD per serving in popular CBD products may likely be inadequate. And even if you took dozens of servings to reach the dosage used in these clinical trials, there is still no guarantee of benefit because of how preliminary these findings are.
But while there is a lack of concrete and conclusive evidence about CBD’s effects, there is considerable hope. Recent legislative changes around hemp and CBD in the US and across the world have enabled numerous human clinical trials to begin, investigating the use of CBD for conditions such as autism, chronic pain, mood disorders, alcohol use disorder, Crohn’s disease, graft-versus-host-disease, arthritis and cancer- and cancer-treatment-related side effects such as nausea, vomiting and pain. The results of these studies should become available over the next five years.